
VC-backed Biocartis lists with €450m market cap
Biocartis, a Belgian molecular diagnostics company backed by several venture capital firms, has listed on the Euronext Brussels.
With a final offer price set at €11.50 per share, Biocartis reached a market cap of €450m (or €465m, assuming the full exercise of the over-allotment option). The offering solely comprised new shares, allowing the business to raise €100m prior to the exercise of the over-allotment option. Shares started trading on Euronext Brussels on 27 April.
KBC Securities acted as sole global coordinator in the offering. KBC Securities, Kempen & Co and Petercam acted as joint bookrunners.
Existing Biocartis shareholders committed to subscribe for an overall €21.5m as part of the IPO.
Previous funding
The company has been the recipient of a number of funding rounds over the past few years. Biocartis's series-A round took place in October 2009 – Advent Venture Partners, Biovest, KBC Private Equity and Aescap Venture provided €10m to the company.
Biovest, Advent and Aescap committed a further €30m the following April, alongside Johnson & Johnson Development Corporation (JJDC) and Debiopharm in the company's series-B.
PMV then invested in the company in November 2011 as part of a €71m series-C round. The capital injection was provided by a large consortium comprising PMV, Debiopharm, Philips, Valiance, Biovest, Wellcome Trust, New Rhein Healthcare, several family offices and members of Biocartis's senior management team.
The company's series-D round took place in December 2012, with PMV providing €11m of the €34.5m funding round. The majority of the business's previous backers reinvested in the round. The company then raised €30m in its series-E round from a group of investors including PMV, Debiopharm Diagnostics and JJDC at the end of 2013.
Biocartis most recently raised €64.5m from its backers in September 2014.
Company
Founded in 2007, Biocartis develops diagnostics systems with the aim of providing point-of-need personalised diagnostics tests. Its diagnostics platforms are designed predominantly for molecular oncology applications. The company is headquartered in Mechelen, Belgium.
People
Rudi Pauwels is CEO and founder of Biocartis.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater